Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.73 +0.70 (+4.11%)
Official Closing Price Updated: 4:10 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,190,810
Open 17.07
Bid (Size) 16.00 (200)
Ask (Size) 18.00 (100)
Prev. Close 17.03
Today's Range 16.95 - 17.91
52wk Range 10.45 - 17.86
Shares Outstanding 354,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for. 
Via StockStory
Topics World Trade
News headline image
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Bankruptcy Stocks

Performance

YTD
+6.9%
+6.9%
1 Month
+3.7%
+3.7%
3 Month
+18.2%
+18.2%
6 Month
+22.6%
+22.6%
1 Year
+8.4%
+8.4%

More News

Read More
News headline image
1 Healthcare Stock to Research Further and 2 Facing Headwinds
Via StockStory
Topics Stocks
News headline image
3 Stocks Under $50 That Fall Short
Via StockStory
News headline image
3 Cash-Burning Stocks We’re Skeptical Of
Via StockStory
Topics Bankruptcy
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Question
Via StockStory
News headline image
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year ↗
Via The Motley Fool
News headline image
Bausch + Lomb Announces Two Board of Directors Appointments
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Why Bausch + Lomb (BLCO) Stock Is Trading Up Today
Via StockStory
Topics Artificial Intelligence Initial Public Offering
News headline image
3 Healthcare Stocks We Think Twice About
Via StockStory
Topics Stocks
News headline image
BLCO Stock Still 16% Below IPO — Is Silver Point’s $38.7 Million Bet a Turning Point? ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why Bausch + Lomb (BLCO) Stock Is Up Today
Via StockStory
Topics Economy Initial Public Offering
News headline image
3 Small-Cap Stocks with Warning Signs
Via StockStory
News headline image
3 Cash-Burning Stocks We Approach with Caution
Via StockStory
News headline image
Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
News headline image
Bausch + Lomb to Participate in Citi Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers
Via StockStory

Frequently Asked Questions

Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 17.73
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 02/17/26 04:10 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 6.28B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.